OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
49
Results
Show all
Save search
Copy query
Show results for
Unknown
(49)
Publication Date
Release Date
2024
(7)
2016
(7)
2023
(6)
2022
(4)
2019
(4)
2018
(4)
2025
(3)
2021
(3)
2013
(3)
2015
(2)
2012
(2)
2020
(1)
2017
(1)
2014
(1)
2011
(1)
Previous
page
1 / 5
You're on page
1
page
2
page
3
page
4
page
5
Next
page
Sort
by:
Relevance
Page size
10
Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial.
Not available
S-EPMC6771504
|
biostudies-literature
Cite
Nivolumab versus investigator's choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age.
Not available
S-EPMC7723820
|
biostudies-literature
Cite
Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.
Not available
S-EPMC6563923
|
biostudies-literature
Cite
CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer.
Not available
S-EPMC6221824
|
biostudies-literature
Cite
Acutely blocking excessive mitochondrial fission prevents chronic neurodegeneration after traumatic brain injury.
Not available
S-EPMC11525032
|
biostudies-literature
Cite
Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
Not available
S-EPMC6461049
|
biostudies-literature
Cite
Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use.
Not available
S-EPMC7721346
|
biostudies-literature
Cite
Tipifarnib in Head and Neck Squamous Cell Carcinoma With
HRAS
Mutations.
Not available
S-EPMC8189627
|
biostudies-literature
Cite
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.
Not available
S-EPMC5564292
|
biostudies-literature
Cite
Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141.
Not available
S-EPMC8895496
|
biostudies-literature
Cite
Previous
page
1 / 5
You're on page
1
page
2
page
3
page
4
page
5
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets